Literature DB >> 28318778

Stenotrophomonas maltophilia healthcare-associated infections: identification of two main pathogenic genetic backgrounds.

C Corlouer1, B Lamy2, M Desroches3, J Ramos-Vivas4, E Mehiri-Zghal5, O Lemenand6, J-M Delarbre7, J-W Decousser8.   

Abstract

BACKGROUND: Stenotrophomonas maltophilia is an opportunistic multi-drug-resistant bacterium responsible for healthcare-associated infections. Strategies for in-hospital infection control and management of carriers and environmental reservoirs remain controversial. AIM: To determine the population structure of S. maltophilia strains in hospitalized infected patients and to identify putative highly pathogenic subpopulations that require upgraded infection control measures.
METHODS: Eighty-three diverse human strains of various clinical origins from 18 geographically distant hospitals were characterized phenotypically and genotypically using a multi-locus sequence typing (MLST) approach.
FINDINGS: Neither a predominant nor emerging sequence type (ST) was identified. Among the 80 typeable strains, only 29% corresponded to described STs, especially ST5 (N=6) and ST4/26/31 (N=2). The ST distribution and the phylogenic tree based on the concatenated MLST genes did not account for geographical, clinical origin or antimicrobial susceptibility clustering. A phylogenic tree that included 173 ST profiles from the MLST database and the 80 typeable strains confirmed the high genetic diversity of S. maltophilia, the previously reported genogroup organization and the predominance of genogroup 6, as it represented 41% (33/80) of the strains. Unexpectedly, genogroup 2 was the second most prevalent genogroup and included 16% (13/80) of the strains. These genogroups represented 57% (20/35) of the strains in respiratory patients and 75% (9/12) of the strains in patients with cystic fibrosis.
CONCLUSION: Beyond MLST, the over-representation of some genogroups among strains responsible for healthcare-associated infections was confirmed. Genogrouping affiliation is recommended to implement infection control measures selectively for the most pathogenic strains isolated from patient or environmental reservoirs.
Copyright © 2017 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Genogroup; MLST; Nosocomial; Stenotrophomonas maltophilia

Mesh:

Year:  2017        PMID: 28318778     DOI: 10.1016/j.jhin.2017.02.003

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  10 in total

Review 1.  Clinical challenges treating Stenotrophomonas maltophilia infections: an update.

Authors:  Maria F Mojica; Romney Humphries; John J Lipuma; Amy J Mathers; Gauri G Rao; Samuel A Shelburne; Derrick E Fouts; David Van Duin; Robert A Bonomo
Journal:  JAC Antimicrob Resist       Date:  2022-05-05

2.  Are animals a source of Stenotrophomonas maltophilia in human infections? Contributions of a nationwide molecular study.

Authors:  Aurélie Jayol; Camille Corlouer; Marisa Haenni; Mélanie Darty; Karine Maillard; Marine Desroches; Brigitte Lamy; Estelle Jumas-Bilak; Jean-Yves Madec; Jean-Winoc Decousser
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-02-27       Impact factor: 3.267

3.  Interactions of Aspergillus fumigatus and Stenotrophomonas maltophilia in an in vitro Mixed Biofilm Model: Does the Strain Matter?

Authors:  Elise Melloul; Lolita Roisin; Marie-Fleur Durieux; Paul-Louis Woerther; Delphine Jenot; Veronica Risco; Jacques Guillot; Eric Dannaoui; Jean-Winoc Decousser; Françoise Botterel
Journal:  Front Microbiol       Date:  2018-11-27       Impact factor: 5.640

4.  Population Structure, Molecular Epidemiology, and β-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States.

Authors:  Maria F Mojica; Joseph D Rutter; Magdalena Taracila; Luciano A Abriata; Derrick E Fouts; Krisztina M Papp-Wallace; Thomas J Walsh; John J LiPuma; Alejandro J Vila; Robert A Bonomo
Journal:  mBio       Date:  2019-07-02       Impact factor: 7.867

5.  Characterization of Phenotypic and Genotypic Diversity of Stenotrophomonas maltophilia Strains Isolated From Selected Hospitals in Iran.

Authors:  Narjess Bostanghadiri; Zohreh Ghalavand; Fatemeh Fallah; Abbas Yadegar; Abdollah Ardebili; Samira Tarashi; Abazar Pournajaf; Jalal Mardaneh; Saeed Shams; Ali Hashemi
Journal:  Front Microbiol       Date:  2019-05-29       Impact factor: 5.640

6.  Discrimination of biofilm-producing Stenotrophomonas maltophilia clinical strains by matrix-assisted laser desorption ionization-time of flight.

Authors:  Edeer Montoya-Hinojosa; Paola Bocanegra-Ibarias; Elvira Garza-González; Óscar Manuel Alonso-Ambriz; Gabriela Aimee Salazar-Mata; Licet Villarreal-Treviño; Eduardo Pérez-Alba; Adrián Camacho-Ortiz; Rayo Morfín-Otero; Eduardo Rodríguez-Noriega; Samantha Flores-Treviño
Journal:  PLoS One       Date:  2020-12-31       Impact factor: 3.240

7.  Advances in the Microbiology of Stenotrophomonas maltophilia.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2021-05-26       Impact factor: 50.129

8.  Raman-Deuterium Isotope Probing for in-situ identification of antimicrobial resistant bacteria in Thames River.

Authors:  Yizhi Song; Li Cui; José Ángel Siles López; Jiabao Xu; Yong-Guan Zhu; Ian P Thompson; Wei E Huang
Journal:  Sci Rep       Date:  2017-11-30       Impact factor: 4.379

9.  Evolution of Stenotrophomonas maltophilia in Cystic Fibrosis Lung over Chronic Infection: A Genomic and Phenotypic Population Study.

Authors:  Alfonso Esposito; Arianna Pompilio; Clotilde Bettua; Valentina Crocetta; Elisabetta Giacobazzi; Ersilia Fiscarelli; Olivier Jousson; Giovanni Di Bonaventura
Journal:  Front Microbiol       Date:  2017-08-28       Impact factor: 5.640

10.  Evaluation of a Stenotrophomonas maltophilia bacteremia cluster in hematopoietic stem cell transplantation recipients using whole genome sequencing.

Authors:  Stefanie Kampmeier; Mike H Pillukat; Aleksandra Pettke; Annelene Kossow; Evgeny A Idelevich; Alexander Mellmann
Journal:  Antimicrob Resist Infect Control       Date:  2017-11-13       Impact factor: 4.887

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.